Recently in the advanced pharmaceutical industry, the importance of collaborative research and development in which clinical researchers at hospitals actively participate from the early stages of development has emerged for the reduction of R&D cost and the successful drug development. In particular, as the paradigm shifts towards the development of and more innovative therapeutics such as precision medicine, companion diagnostics and immuno-oncology as well as overcoming cancer drug resistance, there is even greater demand for in-depth clinical expertise especially at the translational/preclinical development stage.
Asan Medical Center, an internationally renowned medical center, has established a unique cancer-specific efficacy evaluation platform based on the infrastructure of a oncology-specialized hospital and also achieved remarkable accomplishments through the Center for Development and Commercialization of Anti-cancer Therapeutics (CDCAT, 2010-2015), the T2B (Technology to Business) Infrastructure Center for Advancing Cancer Therapeutics (CACT, 2015-2020) and the Asan Preclinical Evaluation center for cancer therapeutiX (APEX, 2020-2023) , where a number of pipelines have been accelerated into clinical trials and/or successful technology transfer for further development and commercialization.
Based on these achievements and experience, the Asan Preclinical Evaluation center for cancer therapeutiX (APEX+, 2023-2027) was granted and designated by Ministry of Health and Welfare to promote clinically valid translational/preclinical research in cancer therapy.
Here in APEX, groups of oncology specialists and translational researchers with extensive experience are committed to accelerating drug development and commercialization as well as adding clinical value to your pipelines. APEX will continue to develop pioneering, challenging and cutting-edge models in line with rapidly changing global anti-cancer drug development trends.